Cargando…
Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients
BACKGROUND: We have investigated predictors of 90-day-mortality in a large cohort of non-specific cancer of unknown primary patients. METHODS: Predictors have been identified by univariate and then logistic regression analysis in a single-center cohort comprising 429 patients (development cohort). W...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715134/ https://www.ncbi.nlm.nih.gov/pubmed/19649260 http://dx.doi.org/10.1371/journal.pone.0006483 |
_version_ | 1782169749481848832 |
---|---|
author | Penel, Nicolas Negrier, Sylvie Ray-Coquard, Isabelle Ferte, Charles Devos, Patrick Hollebecque, Antoine Sawyer, Michael B. Adenis, Antoine Seve, Pascal |
author_facet | Penel, Nicolas Negrier, Sylvie Ray-Coquard, Isabelle Ferte, Charles Devos, Patrick Hollebecque, Antoine Sawyer, Michael B. Adenis, Antoine Seve, Pascal |
author_sort | Penel, Nicolas |
collection | PubMed |
description | BACKGROUND: We have investigated predictors of 90-day-mortality in a large cohort of non-specific cancer of unknown primary patients. METHODS: Predictors have been identified by univariate and then logistic regression analysis in a single-center cohort comprising 429 patients (development cohort). We identified four predictors that produced a predictive score that has been applied to an independent multi-institutional cohort of 409 patients (validation cohort). The score was the sum of predictors for each patient (0 to 4). RESULTS: The 90-day-mortality-rate was 33 and 26% in both cohorts. Multivariate analysis has identified 4 predictors for 90-day-mortality: performance status>1 (OR = 3.03, p = 0.001), at least one co-morbidity requiring treatment (OR = 2.68, p = 0.004), LDH>1.5×the upper limit of normal (OR = 2.88, p = 0.007) and low albumin or protein levels (OR = 3.05, p = 0.007). In the development cohort, 90-day-mortality-rates were 12.5%, 32% and 64% when the score was [0–1], 2 and [3]–[4], respectively. In the validation cohort, risks were 13%, 25% and 62% according to the same score values. CONCLUSIONS: We have validated a score that is easily calculated at the beside that estimates the 90-days mortality rate in non-specific CUP patients. This could be helpful to identify patients who would be better served with palliative care rather than aggressive chemotherapy. |
format | Text |
id | pubmed-2715134 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-27151342009-08-03 Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients Penel, Nicolas Negrier, Sylvie Ray-Coquard, Isabelle Ferte, Charles Devos, Patrick Hollebecque, Antoine Sawyer, Michael B. Adenis, Antoine Seve, Pascal PLoS One Research Article BACKGROUND: We have investigated predictors of 90-day-mortality in a large cohort of non-specific cancer of unknown primary patients. METHODS: Predictors have been identified by univariate and then logistic regression analysis in a single-center cohort comprising 429 patients (development cohort). We identified four predictors that produced a predictive score that has been applied to an independent multi-institutional cohort of 409 patients (validation cohort). The score was the sum of predictors for each patient (0 to 4). RESULTS: The 90-day-mortality-rate was 33 and 26% in both cohorts. Multivariate analysis has identified 4 predictors for 90-day-mortality: performance status>1 (OR = 3.03, p = 0.001), at least one co-morbidity requiring treatment (OR = 2.68, p = 0.004), LDH>1.5×the upper limit of normal (OR = 2.88, p = 0.007) and low albumin or protein levels (OR = 3.05, p = 0.007). In the development cohort, 90-day-mortality-rates were 12.5%, 32% and 64% when the score was [0–1], 2 and [3]–[4], respectively. In the validation cohort, risks were 13%, 25% and 62% according to the same score values. CONCLUSIONS: We have validated a score that is easily calculated at the beside that estimates the 90-days mortality rate in non-specific CUP patients. This could be helpful to identify patients who would be better served with palliative care rather than aggressive chemotherapy. Public Library of Science 2009-08-03 /pmc/articles/PMC2715134/ /pubmed/19649260 http://dx.doi.org/10.1371/journal.pone.0006483 Text en Penel et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Penel, Nicolas Negrier, Sylvie Ray-Coquard, Isabelle Ferte, Charles Devos, Patrick Hollebecque, Antoine Sawyer, Michael B. Adenis, Antoine Seve, Pascal Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients |
title | Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients |
title_full | Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients |
title_fullStr | Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients |
title_full_unstemmed | Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients |
title_short | Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients |
title_sort | development and validation of a bedside score to predict early death in cancer of unknown primary patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715134/ https://www.ncbi.nlm.nih.gov/pubmed/19649260 http://dx.doi.org/10.1371/journal.pone.0006483 |
work_keys_str_mv | AT penelnicolas developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients AT negriersylvie developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients AT raycoquardisabelle developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients AT fertecharles developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients AT devospatrick developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients AT hollebecqueantoine developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients AT sawyermichaelb developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients AT adenisantoine developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients AT sevepascal developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients |